Outpatient Therapy denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for outpatient therapy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Outpatient Therapy as Not FDA-Approved

For therapy services (as opposed to drugs or devices), a not-FDA-approved denial is unusual and often reflects a misclassification or a broader coding issue — for example, a new technology, a biofeedback device, or a neurostimulation modality used in a therapeutic context may face this denial. It can also arise when a therapy involves a device component that lacks a specific FDA clearance or when Aetna conflates an experimental-technology classification with an FDA-approval question. Identifying exactly what component triggered this label is the critical first step.

## Why This Denial Is Appealable

Many evidence-based therapeutic modalities operate entirely outside FDA jurisdiction — psychotherapy, physical therapy, occupational therapy, and speech therapy do not require FDA approval of the service itself. If the denial was applied in error to a service-based benefit, that misclassification is directly appealable. If a device or technology component is at issue, FDA 510(k) clearance or a predicate-device pathway may satisfy the plan's requirements, and your provider can document that status.

## Federal Appeal Framework

• ACA §2719 External Review: Non-grandfathered plans must offer IRO external review after internal appeals. The external-review deadline is typically around four months from the denial date — confirm on your EOB.
• ERISA §503: Requires the plan to disclose the specific regulatory basis for the denial and provide full-and-fair review.
• Experimental/investigational review rights: If this denial is substantively an experimental classification, you have specific external-review rights under most state laws and ACA regulations.

## Appeal Timeline

1. Request the full denial file, including the specific Aetna clinical policy bulletin and the regulatory basis cited. 2. Confirm with your provider whether the service, device, or modality has any applicable FDA clearance or falls outside FDA jurisdiction. 3. File an internal appeal with documentation addressing the specific regulatory question raised. 4. Proceed to external review if the internal appeal is denied.

## Documentation to Gather

• Provider clarification letter: Explaining the regulatory status of the therapy, device, or modality — whether FDA clearance exists, and if not, why FDA approval does not apply to this service type.
• FDA clearance documentation (if applicable): 510(k) summary, predicate device listing, or equivalent, obtained from your provider or the device manufacturer.
• Diagnosis and clinical records: Establishing the medical need for the treatment.
• Professional-society guidance: A reference from the applicable guideline organization supporting the modality as a recognized standard of care.

## Criteria-Mapping Structure

Obtain Aetna's clinical policy bulletin and map the regulatory and evidence criteria cited:

| Policy Criterion | Applicable Evidence | |---|---| | FDA approval or clearance required | FDA 510(k) documentation or confirmation that service is not a regulated device | | Service falls within covered benefit category | CPT/HCPCS code and benefit-category documentation | | Consistent with accepted medical practice | Professional-society guideline citation |